pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
550
stories
14d
Novo offers low-dose CagriSema data as approval decision looms
endpoints
14d
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
14d
STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more
stat
14d
Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts
biospace
14d
STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial
stat
14d
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
14d
STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work
stat
14d
Are healthcare systems really ready for GLP-1s?
biopharma dive
16d
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
17d
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
fiercebiotech
17d
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope
fiercebiotech
17d
STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease
stat
18d
Definium’s new psychedelics data, and a reprieve for international scientists
stat
18d
Novo partners with Orbis, deepening investment in oral peptide drugs
biopharma dive
18d
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
18d
STAT+: New startup to test psychedelic-like drug against Parkinson’s symptom
stat
18d
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
biospace
18d
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
fiercebiotech
19d
STAT+: Sen. Warren demands to see Trump drug-pricing pharma contracts, accuses RFK Jr. of hiding them
stat
19d
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
19d
A fourth measles death is reported in Pennsylvania
stat
20d
STAT+: RFK Jr. returns to his roots
stat
20d
STAT+: Medicare to expand its pilot that pays for technology to manage chronic diseases
stat
20d
STAT+: Obesity drugmakers are testing in kids as young as 6
stat
20d
Businesses can now apply for NIH funding
stat
20d
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
fiercebiotech
21d
Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand
biospace
21d
Lilly cans early experimental obesity drug after ‘high bar’ not met
fiercebiotech
21d
STAT+: Definium’s LSD therapy eased anxiety in second large trial
stat
21d
Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
fiercebiotech
← prev
page 4 of 19
next →
